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Hyperlipidemia is a condition of abnormally elevated levels of lipids and/or lipoproteins
in the blood circulation. It is usually accompanied with obesity, type 2 diabetes, insulin
resistance, hypertension and non-alcoholic fatty liver diseases (NAFLD) and has become
a great threat to human health. New therapeutic strategies are needed for the prevention
and treatment of both genetic intervention-induced hyperlipidemia and environmentally
induced hyperlipidemia. In this study, we determined the therapeutic effects of a diseaseprotecting gut bacteria, Akkermansia muciniphila, and an annual legume, fenugreek, on
hypertriglyceridemia induced by genetic depletion of cAMP responsive binding protein H
(CREBH KO) in mice. We found that inoculation of A. muciniphila ameliorates both
acute and chronic hyperlipidemia in mice. Increased colonization of A. muciniphila in
CREBH KO mice enhanced the expression of hepatic LDL receptor and facilitated the
clearance of triglyceride (TG) rich lipoproteins. Moreover, A. muciniphila administration
in mice also alleviated hepatic endoplasmic reticulum (ER) stress and metabolic
inflammation. Feeding CREBH KO mice with a diet containing fenugreek seed (2%) also
attenuated the hypertriglyceridemia caused by depletion of CREBH or induced by a high
fat diet (HFD). Fenugreek seed inhibited hepatic apoB100 biosynthesis and suppressed
very low density lipoprotein (VLDL) assembly and secretion. It further improved insulin
resistance induced by HFD.
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Chapter one
General Introduction
1.1 Obesity
Obesity represents abnormal accumulation of body fat. According to NIH (2009-2010),
the prevalence of overweight, which means the body mass index [BMI] is 25 to 29.9, and
obesity, the BMI is more than 30, was approximately 68.8% in the United States among
adults aged 20 or older. Obesity is not strictly a U.S. phenomenon. It has become a
worldwide epidemic [1, 2]. Obesity is one of the major risk factors of metabolic diseases
such as hypertension, dyslipidemia and insulin resistance and so on[3].
Obesity is induced by calorie accumulation, which means that more calories are absorbed
than consumed. The excess calories are usually stored as adipose tissue which can be
subcutaneous or abdominal. Genetic and environmental factors such as excess intake of
energy-rich foods or even air pollution can all increase the risk of obesity [4, 5]. Studies
have revealed that obesity and metabolic syndrome are associated with the changes of
bacterial divisions [6].

1.2 Lipids and Lipoprotein metabolism
A major proportion of lipids in human and animals are triglycerides (TGs), cholesterol
(CHOL) and phospholipids. Besides these, lipids in the body contain sterols, fat-soluble
vitamins (A, D, E and K), mono- and diglycerides, and so on. Lipids are transported
within lipoproteins in circulation, which is the only way that these fatty substances could
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be dissolved in the blood. Lipoproteins are risk factors for cardiovascular and metabolic
disease.
Structurally, lipoproteins consist of two parts: a core of fats containing TGs, cholesterol
esters (CHOL linked to fatty acids), and fat-soluble vitamins; and a monolayer membrane
consisted of phospholipids and small amounts of free cholesterol. Apolipoproteins
penetrate into or through the monolayer membrane acting as cofactors or ligands for the
process of lipid transport and metabolism.
According to the density, lipoproteins are divided into five classes: chylomicrons (CMs),
very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low
density lipoproteins (LDL) and high density lipoproteins (HDL). Each lipoprotein
contains specific contents of protein, TG, CHOL and cholesterol ester (details showed in
table 1) [7, 8].

Table.1. Major contents of human lipoproteins
chylomicron VLDL

IDL

LDL

HDL

Protein

1%

10%

10%

20%

50%

Triglyceride

88%

56%

29%

13%

13%

Cholesterol

1%

8%

9%

10%

6%

3%

15%

39%

48%

30%

Cholesterol
ester
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Adapted from Biochemistry 2nd Ed. 1995 Garrett & Grisham

CMs are the largest lipoproteins which carry fat from the small intestine to the liver,
skeletal muscle and adipose tissue. In the enterocytes, TGs, CHOL, fat-soluble nutrients
and vitamins are packaged into CMs. The main apolipoprotein contained in CMs is apoB48, which is 48 percent as long as apoB-100. In the blood circulation, TGs in CMs are
hydrolyzed by lipoprotein lipase (LPL) and CMs are converted into CM remnants. The
activation of LPL needs a cofactor, apoC-II in CMs. The CM remnants carry CHOL and
the remaining TG to the liver. The clearance of CM remnants by liver is mediated by the
receptors, one of which is LDL receptor, on the membrane of hepatocytes [9]. The
apolipoprotein E (apoE) on the CM remnants, which is exchanged from HDL, is the
ligand of LDL receptor and facilitates the uptake of CM remnants by the liver.
VLDLs are smaller than CMs. It is assembled and secreted by the liver to transport
endogenously synthesized TGs to peripheral tissues. The biogenesis and secretion of
VLDL by the liver plays an essential role in lipid homeostasis. During the circulation,
LPL removes TGs in VLDLs with the assistance of apoC-II. By the removal of TGs and
the uptake of CHOL, VLDL is converted to IDL. IDL is further converted to LDL via the
hydrolysis of TGs by hepatic lipase.
LDL is smaller than VLDL and IDL and is rich in CHOL. It delivers CHOL to the
peripheral tissues by endocytosis. This process is facilitated by the LDL receptors on the
surface of cells. When CHOL is required by cells, the cells express LDL receptor for the
intake of LDLs. The hepatocytes also express LDL receptors. A proportion of LDLs enter
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the liver to be catabolized. The recognition of LDL with LDL receptors is mediated by
apoB100, the essential apolipoprotein in LDL.
HDL is the smallest lipoprotein. It is referred to as “good” lipoprotein because it carries
CHOL from the peripheral tissues back to the liver. HDL is originated from the liver.
Apolipoprotein A1 is the major apolipoprotein in HDL and plays an important role in the
function of HDL. Lecithin-cholesterol acyltransferase (LCAT) in the outer layer of HDL
esterifies CHOL to form cholesterol esters (CE). HDLs provides apoE, C and CE to CMs
and VLDLs and transports the remaining CHOL to the liver.

Adapted from Durrington, P. et al. 2014, Metabolism of Human Diseases: Organ
Physiology and Pathophysiology.

5

ApoB can be divided into two forms according to its molecular size, apoB100 and
apoB48. In human, ApoB100 is produced by the liver and is the essential structure
protein of VLDL and LDL, while apoB48 is synthesized in the small intestine and is the
main protein in CMs. In mice, however, the expression level of apoB48 is much higher
than that of apoB100 in the liver. ApoB cannot be exchanged from VLDL to other
lipoproteins, making it an ideal marker of VLDL [10]. Both apoB100 and apoE are
capable of binding with LDL receptor and thus mediate the clearance of LDL and CM
remnants respectively. It has been reported that increased level of lipids in the liver can
lead to apoB accumulation and ER stress [11-13].

1.3 Hyperlipidemia
Hyperlipidemia represents an abnormal increase of lipids and/or lipoproteins in blood [2].
There are many conditions that could be covered in hyperlipidemia. But the most
common form is high levels of LDL [14]. It has been widely accepted that
hyperlipidemia is one of the main comorbidities of obesity, since obese people are more
likely to develop hyperlipidemia [15]. The excess lipids in the arteries, the main symptom
of hyperlipidemia, can lead to the development of atherosclerosis and coronary heart
disease [16]. Hyperlipidemia usually complicates with obesity, type 2 diabetes, insulin
resistance, hypertension and non-alcoholic fatty liver diseases (NAFLD) [17, 18]. The
prevalence in the United States is more than thirty percent of the adult population [10].
Hyperlipidemia has become a great threat to the public health [15, 19, 20]. Treatment of
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hyperlipidemia includes dietary and drug treatment. Weight loss is beneficial for
hyperlipidemic patients with obesity. In the diets of patients, saturated fat and CHOL
should be avoided in order to prevent the increase of LDL CHOL. Even in some cases, all
fat should be restricted to prevent the formation of CMs. Drug treatment generally
focused on reducing LDL CHOL [21]. There are some drugs that could be used in
treating hyperlipidemia, such as statins, ezetimibe and so on. However, side effects and
low efficiency remains. Therefore, it is required to find more therapeutic options,
especially for severe and genetic hyperlipidemia. In this study, we determined the
therapeutic effects of Akkermansia muciniphila, a disease protecting gut bacteria and
fenugreek, an annual legume, on hypertriglyceridemia induced by depletion of Cyclic
AMP-responsive element-binding protein H (CREBH) in mice.

1.4 CREBH
CREBH (encoded by the gene CREB3L3) belongs to the CREB/ATF family, and was
identiﬁed as a hepatocyte-speciﬁc endoplasmic reticulum (ER) –bound bZIP transcription
factor [22]. CREBH is expressed only in the liver and the small intestine [23, 24]. The
expression of CREBH is dependent on hepatocyte nuclear factor 4α [25, 26]. It is
activated from precursor protein by cleavage of protease S1P and S2P in Golgi [27].
Mature N-terminal portion was liberated and localized into the nucleus as transcriptional
regulator [27, 28]. In the nucleus, CREBH activates the transcription of genes which is
driven by CRE-containing promoter [29].
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CREBH expression can be induced by fatty acids (FAs) and fasting [30, 31]. And it could
be activated by ER stress. The promoter of CREBH gene contains a peroxisome
proliferator responsive element (PPRE) for PPARα transactivation [32]. PPARα regulates
the genes related with FA oxidation in peroxisomes and mitochondria and thus plays a
crucial role in fasting response [33]. During fasting or exposure to synthetic agonists such
as fibrates, adipose tissue would secrete increased concentrations of FFA, which further
activates PPARα. Studies has reported that FFA induces CREBH transcription in
hepatocytes [32], possibly by activating PPARα. Furthermore, it has been revealed that
CREBH is involved in the acute phase response [25] and hepatic gluconeogenesis [34].
Recently, it has been revealed that CREBH plays a role in lipid metabolism. TG
concentration in the plasma of CREBH knockout (KO) mice after fasting was higher
compared with that of wild type (WT) mice [26] The TG content was specifically
increased in the VLDL fraction. These mice have reduced mRNA expression levels of
several genes involved in TG metabolism in the liver. The increase of the plasma TG
appears to be induced by impaired TG clearance [26]. On the other hand, overexpression
of CREBH in mice reduced the plasma TG levels [26]. Interestingly, there are some
nonsynonymous and insertional mutations within the CREBH gene in some individuals
with hypertriglyceridemia, but not in normolipidemic controls [26].

1.5 Microbiota and Akkermansia muciniphila
1.5.1

Microbiota

Microbiota is the general term indicating all the microorganisms in the body of animals
or humans. In the GI tract of human, there are as many as 10 to 100 trillion
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microorganisms. It is approximately 10 times more than the amount of human body cells
[35]. The component of human microbiota is complex. The major part of microbiota is
prokaryotes, most of which are bacteria [36, 37]. The other small part consists of
eukaryotes and viruses [37]. Most of the bacteria in human are located in ileum, the
terminal part of small intestine, and the large intestine. The major energy source of
microbiota is undigested components from the diet of human. Carbohydrates, most of
which are oligosaccharides, such as fibers, resistant starch and non-starch
polysaccharides, are the main substrates that would be metabolized by microbiota [20,
38]. Moreover, microbiota could also ferment some metabolites of the host, like
glycosylated protein mucins, immunoglobulins and lipid derivatives [39, 40]. Numerous
of products of the fermentation include gases and short chain fatty acids (SCFA). Some
metabolic products of the microbiota are beneficial for the host. For instance, the
fermentation of resistant starch would produce butyrate, which is a kind of energy source
of host epithelial cells and could stimulate cell proliferation [41].
Louis Pasteur in 1897 first discovered that the microbiota was crucial for the host [42].
Studies on germ-free animals investigated the importance of microbiota. Germ free
animals are animals that have no bacteria in their body, which are important model to
study the function of microbiota. It was showed that the life span of germ free animals
were short [43]. Microbiota is very important in the metabolism and physiology of
animals [35]. It has been reported that microbiota could impact the glucose metabolism
[44-48] and energy homeostasis [6, 45, 49, 50]. It was also associated with obesity, lowgrade inflammation, diabetes and cancers [50]. Studies have confirmed that
conventionally raised mice with microbiota in their bodies developed more fat mass,
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which is about 40% more, than germ-free mice [49]. Compared with gut microbiota from
lean mice, transplanting isolated gut microbiota from obese mice to germ-free mice
would stimulate the mice to get more body fat [6]. Another study showed that high fat
diet was not able to induce obviously increased body weight in germ-free mice,
suggesting a connection between gut microbiota and weight gain [51]. Gut microbiota
was strongly influenced by high fat diet feeding, and further induced inflammatory
responds and insulin resistance [45, 52-54]. A high fat diet, however, could not induce
germ-free mice to develop inflammation or insulin resistance [55, 56]. Inoculation of
strain Enterobacter cloacae B29, which is a kind of gut bacteria in an obese human, into
germ-free mice triggered obesity with a high fat diet [56]. Beneficial bacteria were found
to be reduced in metabolic complex animal models. The composition modulation of gut
microbiota affected by high fat diet has been reported. Hildebrandt et al. confirmed that
Firmicutes and Proteobacteria would increase while Bacteriodetes would decrease in
mice treated with high fat diet [57]. Murphy et al. also found abundant Firmicutes and
reduced Bacteroidetes in similar condition [58]. It has been widely accepted that gut
microbiota play a role in the metabolism of the host. However, the exact mechanism of
the interaction between gut microbiota and the host is still unclear [59].
1.5.2

Akkermansia muciniphila

A. muciniphila was first isolated from the fecal sample of a Caucasian female [60, 61]. So
far, it has been discovered in the intestines of different animals, which includes rodents,
rabbits, donkeys, pigs, horses and so on [62-66]. A. muciniphila is the first kind of
bacterium isolated from human which belongs to the phylum Verrucomicrobia [67]. The
medium used to isolate A. muciniphila contained only one carbon source, mucin [61]. A.

10

muciniphila is localized in the mucus layer of the intestine [67]. One evidence was that A.
muciniphila could metabolize mucin [61]. Another study showed that A. muciniphila was
one of the first prior utilizers of the mucus in the mice intestine [68]. It has been reported
that A. muciniphila is more abundant in colon than in the ileum [69, 70]. It makes up
more than 1% of the whole microbiota in human feces [67].
Interestingly, it has been revealed that the relative abundance of A. muciniphila increased
under the conditions of caloric restriction in humans, mice, hamsters and snakes [67].
Mucosal analysis also showed that A. muciniphila was abundant in healthy subjects
whereas it was reduced in inflammatory bowel disease (IBD) patients. In contrast, the
amounts of Ruminococcus gnavus in IBD patients increased [71]. Different nutritional
interventions and pharmaceutical treatments could affect the level of A. muciniphila. [67].
Some studies reported that the administration of some special dietary components,
including complex polyphenols, oligofructose, dietary resistant starch, whole grain barley
and so on, which improved the health of the host also increased the abundance of A.
muciniphila [72-74]. High fat diet, however, would decrease A. muciniphila population
[59, 75, 76]. A kind of antidiabetic drug, metformin, was investigated to be able to
improve the proportion of A. muciniphila in mice and stimulate the growth of A.
muciniphila in vitro [76, 77]. Flos Lonicera and ganoderma lucidum that are used as
medicine in Asia, also enhanced the population of A. muciniphila [78-80]. Several studies
revealed the association between the reduction of A. muciniphila abundance and various
metabolic disorders and diseases, including obesity and related disorders and intestinal
diseases [67]. Studies focusing on mouse models which developed obesity or other
symptoms of metabolic disorder induced by genetic depletion, for example, leptin
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deficiency [59, 81], or diet (high fat diet) [82, 83] showed that the abundance of intestinal
A. muciniphila decreased in these models [67]. Remarkably, it has been reported that
daily gavage of A. muciniphila improved the metabolic parameters of mice fed with high
fat diet. It prevented weight gain, restored glucose tolerance and epithelial integrity, and
counteracted metabolic endotoxemia [59, 76]. Another study also proved that A.
muciniphila administration significantly decreased body fat and insulin resistance of a
mouse strain which is prone to obesity (AxB19) [84]. These studies suggested that A.
muciniphila played a role in reducing body fat accumulation and improving insulin
resistance. However, there are also conflicting data. Rat studies reported increased
abundance of A. muciniphila in rats fed with high fat diet [85-87]. Further studies should
be conducted to demonstrate the relationship between A. muciniphila and the metabolism
of the host. In this study, we investigated the effect of A. muciniphila on
hypertriglyceridemia induced by genetic depletion of CREBH in mice and tried to figure
out the underlying mechanism.

1.6 Fenugreek
Fenugreek is an annual legume which belongs to Fabaceae family. It is one of the oldest
Fabaceae family plant used as medicine in central Asia around 4000 BC [88]. It is now
being commercially grown in various countries distributed in South Asia, Middle East,
Europe, Africa and America [89]. Fenugreek seed is the most valuable part of the plant. It
is rich in fiber, proteins, neural lipids, vitamins and minerals. The fiber in fenugreek
seeds is mainly non-starch polysaccharides [88]. Fenugreek fiber plays a role in
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moderating glucose metabolism in human. It helps to reduce glucose absorption, regulate
sugar level and facilitates insulin action [88]. For instance, a study showed that
galactomannans, a main soluble fiber in fenugreek seeds, lowered glucose absorption [88,
90]. Moreover, the special materials, mucilage, tannins, pectin and hemicellulose, in the
seeds inhibit the absorption of bile salt in the colon and hence reduce the LDL level in the
blood [88, 91]. Proteins in fenugreek seeds mainly include albumin, globulin and lecithin
[88]. It contains a large amount of free amino acids, especially histidine and 4hydroxyisoleucine. Theses amino acids may play a role in improving insulin activity [92].
Fenugreek is also rich in alkaloids, flavonoids, saponins and other antioxidants, which
makes fenugreek possess a powerful antioxidant property [88]. All these compounds
could help to ameliorate hypercholesterolemia, diabetes and even cancer [90, 91, 93]. In
many Asian and African civilizations, fenugreek seeds were used as part of the medicine
to treat diabetes [92, 94]. Fenugreek has various pharmacological properties [95]. The
polyphenolics in fenugreek could inhibit peroxidation and attenuate oxidative hemolysis
of erythrocytes in humans [88]. Studies have reported that the optimal consumption may
decrease the TG and CHOL level in the blood (Afef et al., 2000) [96], prevent cancer [97]
and control diabetes mellitus [98]. It has also been investigated that the ethyl acetate
extract of fenugreek seeds reduced TG and CHOL in LDL while increased CHOL
contained in HDL [99]. Due to its unique properties, here we studied whether fenugreek
seeds were capable of alleviating genetic hyperlipidemia in mice and explored the
mechanism of the regulatory effect of fenugreek seeds on the mouse lipid homeostasis.

1.7 Working Hypothesis
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We hypothesized that increased colonization of A. muciniphila could protect the host
from hyperlipidemia by enhancing the uptake of lipoproteins and alleviating hepatic ER
stress and the inflammatory response in CREBH-null mice and that fenugreek seeds
could improve hyperlipidemia by inhibiting the biosynthesis of lipoproteins and
ameliorating insulin resistance.

1.8 Study Aims
Specific Aim 1:
Determine the impact and mechanism of A. muciniphila on hyperlipidemia. Firstly, we
will explore the impact of A. muciniphila on acute (olive oil gavage) and chronic
(CREBH depletion) hyperlipidemia in mice. To figure out the mechanism of the
regulatory effect of A. muciniphila on the host, we will subject different mice models
with vehicle (as control), heat-inactive A. muciniphila and active A. muciniphila. Lipid
content and lipoprotein levels in the plasma and liver of the mice will be measured to
demonstrate if they are impaired by A. muciniphila inoculation. LDL receptor KO mice
will be treated with A. muciniphila to verify whether LDL receptor plays an important
role in the interaction of A. muciniphila and the host. And also, the mRNA and protein
levels of LPL co-factors and the biomarkers of ER stress and inflammation factors in the
liver of the mice will be analyzed to investigate whether A. muciniphila administration is
able to alleviate hepatic stress and inflammation.
Specific Aim 2:
Determine the impact and mechanism of fenugreek hyperlipidemia induced by CREBH
depletion.
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Firstly, we will feed CREBH KO mice with fenugreek seeds rich diet to investigate the
impact of fenugreek seeds on the hyperlipidemia of the mice. And hepatic expression
level of apoB and lipid content will be measured to study the effect of fenugreek on
VLDL assembly. Impact of fenugreek seeds on insulin resistance induced by high fat diet
will also be explored.
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Chapter Two
Materials and Methods
2.1 Animals and animal experimental protocols
Three kinds of mice models were used during the experiments. Wide type (C57BL/6J)
miceand LDLR KO mice (B6.129S7-Ldlrtm1Her/J) were got from the Jackson Laboratory,
Maine, US. Heterozygous CREBH KO mice were kindly provided by Dr. Zhang
Kezhong’s lab. Animals were housed in a 12h light and dark cycle with free access to
food and water. A standard chow diet was provided to the mice which contains 62.1%
carbohydrate, 24.6% protein, and 13.2% fat (kcal/100 kcal) (Dyets Inc., USA). Both male
and female mice were used during the experiment. And the mice used were 12 to 14
weeks old.
For A. muciniphila treatment experiments, CREBH KO mice were divided into 3 groups,
which are control group, heat-inactivated A. muciniphila treatment group, and active A.
muciniphila treatment group (n=6-12/per group). Both WT mice and LDLR KO mice
were divided into 2 groups, which are control group and active A. muciniphila treatment
group. In control group, the mice were administrated by oral gavage with 200 µL PBS
that contained 25% (vol/vol) glycerol, which was the dissolving solution of A.
muciniphila bacteria. In the heat-inactivated A. muciniphila treatment group, the mice
were administrated by oral gavage with 200 µL heat-inactivated A. muciniphila with a
final concentration of 10^9 CFU/mL. In the active A. muciniphila group, the mice were
administrated with 200 µL (10^9 CFU/mL) A. muciniphila by oral gavage. The
administration was conducted every 2 days for two weeks. During the treatment, blood
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samples was collected from submandibular vein after the mice were fasted overnight for
12 hours and the TG and CHOL concentrations of the plasma were monitored every week.
For fenugreek treatment experiments, both WT mice and CREBH KO mice were divided
into control group and fenugreek group. WT mice were fed with high fat diet, which
contains 60% fat and 20% carbohydrate (kcal/100g) (Dyets Inc., USA). CREBH KO
mice were fed with standard chow diet. In fenugreek group, fenugreek seeds were added
into the diet according to a ratio of 2% (g/g). Fenugreek seeds were kindly provided by
Dr. Dipak Santa. All the mice were fed for 7 weeks. Weight of the mice and the food
intake amount were monitored every week.
Mice were euthanized by isoflurane (3% mixed with oxygen). Blood was obtained from
the heart after the mice were anesthetized by isoflurane, and was collected in lithium
heparin coated capillary tubes (Bd Vacutainer Labware Medical, USA). Blood samples
was then centrifuged at 6000 rpm for 10 mine and plasma was collected and stored at 80 °C for further analysis. Tissues, including liver, duodenum, jejunum, ileum, adipose
tissue and muscle, were snap frozen in liquid nitrogen and stored at -80 °C for further
analysis. All the animal care, treatment and experiments were approved by the University
of Nebraska-Lincoln Institutional Animal Care and Use Committee.
2.2 Preparation of A. muciniphila bacterial stocks
The bacteria A. muciniphila MucT (ATTC BAA-835) were purchased from American
Type Culture Collection (ATCC). The bacteria were cultured in brain heart infusion agar
(BD 211065) or broth (BD 237500) medium. And then the bacteria were washed and re-
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suspended in anaerobic PBS which included 25% (vol/vol) glycerol. The stocks were
frozen and stored at -80 °C immediately.
Plate counting was used to determine the concentration (CFU/mL) of the bacteria in the
stocks. Three representative samples were gradient diluted into 4 concentrations
respectively and inoculated in plates with mucin media containing 1% agarose. The
average amount of the bacterial colonies were used to calculate the bacteria concentration
in the stocks. Before used to administrate the mice, the bacteria were diluted to a final
concentration of 10^9 CFU/mL with anaerobic PBS that contained 25% (vol/vol)
glycerol. All the culture and preparation procedures were under strict anaerobic
conditions.
2.3 In vivo chylomicron collection assay
Mice were fasted overnight for 12 hours and then administrated with 200 µL virgin olive
oil (Great Value, Walmart) by oral gavage. 20 min after olive oil gavage, the mice were
treated with poloxamer 407 (Pluronic F-127, Sigma) by intraperitoneal (IP) injection
according to an amount of 500 mg/kg. Poloxamer was mixed into saline to make a 20%
solution one day before treatment and given 2.5 µL/g body weight by IP. The mice were
euthanized at 2 hours after poloxamer treatment. Before olive oil administration, baseline
blood (0h) was collected from submandibular vein for the baseline lipid and protein
contents determination. One hour after poloxamer treatment, blood samples were
collected via submandibular vein. When sacrifice, final blood (2h) was collected via
cardiac puncture. All the blood samples were centrifuged at 6000 rpm for 10 min for the
plasma separation. Plasma and tissues were collected and stored at -80°C for further
experiments.
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2.4 Vitamin A excursion assay
Vitamin A excursion assay was used as a method to measure the clearance of CMs
derived from dietary fats [100]. Mice were fasted for 4 hours and then administrated with
mixture of olive oil and [11, 12-3H]-retinol by oral gavage. 1 mL olive oil was mixed
with 27 μCi of [11, 12-3H]-retinol (PerkinElmer) in ethanol. Submandibular vein blood
was sampled at 0h (baseline), 2h, 3.5h, 7.5h and 11h for determining the radioactivity in
the blood. Baseline blood was collected before gavage. 10 µL of serum was used to
detect the 3H level by scintillation counting. The measurement was conducted in
triplicate. At 11 hours after fat administration, mice were euthanized. Cardiac puncture
was conducted to collect the blood samples. Plasma and tissues were stored at -80°C for
further experiments.
2.5 Lipoprotein Characterization
Gel filtration fast protein liquid chromatography (FPLC) was used to separate the
lipoproteins subclasses in the plasma [101]. 150 µL plasma samples were injected onto a
Superose 6 10/200 GL column (Amersham Pharmacia Biotechnology, Piscataway, NJ).
The flow rate of the whole process was 0.5 ml/min. Specific eluent was used to elute the
different fractions from the column. And the TG and CHOL concentrations of each
fractions were measured. The receipt of the eluent is: 10 mM Tris, 150 mM NaCl, 2 mM
CaCl2, 100 μM DTPA, 0.02% NaN3, pH 7.4.
2.6 Immunoblot analysis
Tissue Lysate Preparation: 100mg tissue (liver or jejunum) was homogenized in 200 µL
RIPA buffer in 1.5mL microfuge tube using tissue homogenization mixer (VWR
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International, Radnor, PA) till there was no fragment left. Then add 800 µL RIPA buffer
and mix completely by vortex. Sonicate for 3 × 10 seconds. And keep the samples in ice
for 10 min. After centrifuging at 12000 rpm for 10 min at 4°C in a Heraeus Biofuge Pico
centrifuge (Thermo Electron Corporation Canada, Gormley, ON), carefully transfer the
protein lysate under the fat cake to a new 1.5mL microfuge tube. The lysates were then
mixed with 4 × SDS Loading Buffer by vortex and heated at 100°C for 6 to 10 min. The
samples could be stored at -80°C before further analysis.
Plasma Lysate Preparation: 2 µL plasma was mixed with 98 µL RIPA buffer. Then add
100 µL 2 x SDS loading buffer and mix the lysate by vortex. After that, the lysates were
boiled at 100°C for 6 to 10 min and stored at -80°C for further analysis.
The receipt of RIPA buffer is: 150 mM sodium chloride (NaCl) (Fisher Scientific,
Waltham, MA), 10 mM tris (hydroxymethyl) aminomethane (Tris) (pH 7.4) (Fisher
Scientific, Waltham, MA), 1 mM ethylenediaminetetraacetic acid (EDTA) (SigmaAldrich Canada Ltd., Oakville, ON), 1% Nonidet P-40 (Sigma-Aldrich Canada Ltd.,
Oakville, ON), and protease inhibitor cocktail tablet (Roche Applied Science, Laval,
QC.).
The receipt of 4x SDS loading buffer is: 200mM Tris-HCl, pH6.8 (Fisher Scientific,
Waltham, MA), 8% SDS (Fisher Scientific, Waltham, MA), 40% Glycerol (Fisher
Scientific, Waltham, MA) and 0.002% Bromophenol Blue (Sigma-Aldrich, St. Louis,
MO). Before use, add 200mM DTT immediately from a 1M DTT stock. The buffer could
be stored at -20℃ for up to 6 months.
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Western Blotting Analysis: Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed for protein detection. 6% acrylamide gels were used for
apoB detection, 8% acrylamide gels were for Toll-like Receptor 4 (TLR4), and 10% for
all other proteins. Running buffer contained 25 nM Tris, 192 mM glycine (Fisher
Scientific, Waltham, MA) and 0.1% SDS. And a mini-PROTEAN electrophoresis system
(Bio-Rad Laboratories Ltd., Mississauga, ON) was used as the power supply for
electrophoresis and transfer. Proteins in gels were transferred onto polyvinylidene
fluoride (PVDF) membranes (PerkinElmer, Woodbridge, ON) under a voltage of 40V at
4°C overnight using a wet transfer apparatus (Bio-Rad Laboratories Ltd., Mississauga,
ON). Transfer buffer contained 190 mM glycine, 25 mM Tris and 10% methanol which
was freshly prepared.
Membranes were then blocked in 5% milk (Bio-Rad Laboratories Ltd., Mississauga, ON)
in 1x TBST for at least 2 hours at room temperature on an orbital shaker. The receipt of
TBST is 10 mM Tris, 150 mM NaCl and 0.05% triton x 100 (Fisher Scientific, Waltham,
MA). After blocking, membranes were washed in 1x TBST 5 times for 5 min using 1x
TBST. Then the membranes were incubated with primary antibodies overnight at 4°C.
The antibodies were diluted according to the datasheet provided by manufacturers. The
antibodies used are as follows: anti-apoB, anti-apoE and anti-albumin (Midland
Bioproducts, Boone, IA); anti-β-actin (Sigma-Aldrich, St. Louis, MO); anti-TLR4, antiJNK-p, anti-Bip (Cell Signaling, Danvers, MA); and anti-eIF2α (Invitrogen, Carlsbad,
CA). Membranes were then washed 5 times for 5 minutes using 1x TBST and then
incubated with secondary antibody for 1 hour at room temperature. There are three kinds
of secondary antibodies used in the project, including donkey anti-rabbit IgG-HRP (GE

21

Healthcare, Buckinghamshire, UK), sheep anti-mouse IgG-HRP (GE Healthcare,
Buckinghamshire, UK) or donkey anti-goat IgG-HRP (Santa Cruz, Dallas, TX). The antirabbit and anti-mouse antibodies were diluted in 5% milk for 1:2000. And the anti-goat
antibody was diluted in 5% milk for 1:3333. Membranes were washed 5 times for 5
minutes in 1x TBST. Enhanced chemiluminescence reagents (Amersham Biosciences,
Pittsburgh, PA) was used to expose the protein bands on membranes to signals in
autoradiography film (Denville Scientific Inc., Metuchen, NJ) in exposure cassettes
(Eastman Kodak Company, Rochester, NY). Bands were quantified by densitometry
using Image J.
2.7 mRNA analysis by real-time PCR
Total RNA was extracted from liver of mice using TRIzol (Invitrogen, Carlsbad, CA)
according to the protocol that was provided with the reagent by the manufacturer. The
RNA was reversed to cDNA using a high capacity cDNA reverse transcription kit
(Applied Biosystems). The mRNA expression levels of target genes were tested by
quantitative real-time PCR using a SYBR Green PCR Kit (Applied Biosystems, Carlsbad,
CA). The qPCR was conducted with a Prism 7300 Sequence Detecting System (Applied
Biosystems, Carlsbad, CA).
2.8 Lipid extraction and measurement
Lipids were extracted from tissue according to the method mentioned by Folch, J [102].
100 mg of tissues (liver or jejunum) were completely homogenized in 1ml triton lysis
buffer. The homogenate was then put in ice for 30 min for lipid extraction. After adding 2
ml of Folch/BHT reagent, the samples were oscillated by vortex for 3 x 10 sec. Then the
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samples were centrifuged at 2000 rpm for 10 min at RT in a Heraeus Biofuge Pico
centrifuge (Thermo Electron Corporation Canada, Gormley, ON). The lower phase was
moved to new glass reaction tubes and was dried under N2 to about 100 ul. 1ml of
CHCl3 (Fisher Scientific, Waltham, MA) and 1% Triton x 100 in CHCl3 was used to
wash the samples successively. And the reagents were all dried by N2. Samples was
finally diluted in 600ul distilled water and stored at 4°C for further analysis.
2 µL of plasma or the extracted lipid aliquots were used to measure the CHOL and TG
contents using an enzymatic/GPO TG and CHOL assay kit (Pointe Scientific, Canton, MI)
according to the instruction provided by the manufacturer with the kit.
The receipt of Folch/BHT reagent is: 280 ml chloroform(Fisher Scientific, Waltham,
MA), 140 ml methanol(Fisher Scientific, Waltham, MA) and 42mg BHT (to
100ug/ml)( Acros Organics, New Jersey, USA)
The receipt of triton lysis buffer is: 80 mM NaCl (Fisher Scientific, Waltham, MA), 50
mM Tris (pH 8.0) (Fisher Scientific, Waltham, MA), 2 mM CaCl2 (Fisher Scientific,
Waltham, MA), and 1% Triton x 100 (Fisher Scientific, Waltham, MA).
2.9 Glucose tolerance test and insulin tolerance test
For glucose tolerance test, the mice were fasted for 12h overnight. The baseline blood
glucose concentration was tested. Then the mice were treated with glucose by IP injection
or oral gavage according to an amount of 2 μg/g body weight. Blood glucose
concentrations of the mice were then tested at 15, 30, 45, 60 and 120 min after glucose
treatment.
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For insulin tolerance test, the mice were fasted for 4h early in the morning. The baseline
blood glucose levels was tested before insulin treatment. Mice was gave insulin (0.5 U/kg)
(Eli Lilly, Indianapolis, IN) via IP injection. And then glucose levels in the blood of the
mice were measured at 15, 30, 45, 60 and 120 min after insulin treatment.
2.10

Statistical analysis

Digital data were evaluated using GraphPad Prism 5 (La Jolla, CA, USA). In all the
groups throughout the project, at least three subjects were analyzed. T-tests were used to
compare parallel experiments. Results were presented as means ± standard error of the
mean. P values which were less than 0.05 were considered statistically significant and
were marked with a single asterisk (*). P values less than 0.01 were marked with two
asterisks (**).
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Chapter Three
Results
Part 1
Determine the beneficial property of A. muciniphila on genetic induced
hyperlipidemia and the underlying metabolism
Previous study in our lab has investigated that after administrating 200 µL A. muciniphila
(2x10^8 cfu/0.2 mL) to 12-week old WT (C57BL/6J) mice every two days for 2 weeks,
the plasma lipid contents (TG and CHOL) of the mice treated with A. muciniphila were
comparable with that of control group, which was treated with vehicle (PBS containing
25% glycerol) for 2 weeks. To further explore the effects of A. muciniphilaon on the
host’s acute lipid absorption, after 2 weeks of A. muciniphila administration, the mice
were fasted for 12 hours, and then treated with 200 µL olive oil by oral gavage. 500
mg/kg poloxamer was further treated by IP injection at 20 min after oil administration.
Poloxamer could restrain the activity of LPL and suppress the hydrolysis of lipoproteins
in the blood. Protein levels of plasma apoB48, apoB100 and apoE, which were the key
proteins in VLDL and CMs, were analyzed. Protein levels before poloxamer treatment
were comparable between the two groups (Figure 1 A. Data from Xuedong Tong). 2
hours after poloxamer injection, the expression of apoB48 and apoB100 in the plasma of
vehicle group was significantly higher than that of A. muciniphila group (Figure 1 B).
These data were consistent with the result of plasma lipid concentration analysis. The
apoE expression was a little higher in vehicle group. But the difference was not
significant (Figure 1 B). This indicates that the secretion of CMs and VLDL was
increased, or their clearance was decreased in vehicle group.
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(Shen et al. ATVB 2016)
Figure 1. The impact of A. muciniphila on the host’s acute lipid absorption. 12-week old
WT (C57BL/6J) mice was administrated with 200 µL vehicle or A. muciniphila (2x10^8
cfu/0.2 mL) every two days for 2 weeks. Then the mice were fasted for 12 hours, and
then treated with 200 µL olive oil by oral gavage. 500 mg/kg poloxamer was further
treated by IP injection 20 min after oil administration. Protein levels of plasma apoB48,
apoB100 and apoE were analyzed, before and 2 hours after poloxamer treatment. A) The
protein levels before poloxamer treatment were comparable between the two groups
(Data from Xuedong Tong). B) After poloxamer injection, apoB48 and apoB100 levels in
the plasma of vehicle group was significantly higher than that of A. muciniphila group.
Results are shown as means ± SD for two experiments that were performed in triplicate.
*P<0.05, **P<0.01.

26

To investigate the effect of A. muciniphila colonization on chronic hyperlipidemia
induced by gene depletion, CREBH KO mice were used. The depletion of CREBH of
mice could induce hypertriglyceridemia. 200 µL of vehicle or A. muciniphila were
respectively administrated by gavage to two groups of CREBH KO mice for 2 weeks.
Previous study in the lab indicated that plasma TG level of the mouse group treated with
A. muciniphila was significantly lower than that of control group after treated for 2
weeks. To find out if the colonization of A. muciniphila could ameliorate insulin
resistance induced by CREBH depletion, we subjected the two groups of mice to an oral
glucose tolerance test. After glucose delivery, the growth of blood glucose level of A.
muciniphila group was slower than vehicle treatment group (Figure 2 A), indicating that
A. muciniphila could improve glucose intolerance in CREBH KO mice.
To further explore if it is necessary that A. muciniphila is alive to regulate the metabolism
of the host, two groups of CREBH KO mice were subjected with active A. muciniphila
and heat-inactive A. muciniphila every two days for two weeks. The plasma TG level of
heat-inactive A. muciniphila group didn’t decrease after two weeks of administration,
while the plasma TG level of active A. muciniphila group was significantly decreased at
the end of two weeks (Figure 2 C). Oral glucose tolerance test also showed that inactive
A. muciniphila could not improve the glucose tolerance of CREBH KO mice (Figure 2 B).
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(Shen et al. ATVB 2016)
Figure 2. The impact of A. muciniphila colonization on chronic hyperlipidemia induced
by gene depletion. A) 200 µL of vehicle or A. muciniphila were respectively
administrated by gavage to two groups of CREBH KO mice for 2 weeks. At the end of
week 2, the mice were subjected to an oral glucose tolerance test. The alteration of
glucose concentration in the mice blood after glucose treatment was shown in the graph.
B) CREBH KO mice were subjected with active A. muciniphila and heat-inactive A.
muciniphila every two days for two weeks. Oral glucose tolerance test was conducted
after 2-week oral gavage. C) The plasma TG and CHOL levels of heat-inactive A.
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muciniphila group and active A. muciniphila group was compared before and after A.
muciniphila administration. Results are shown as means ± SD for two experiments that
were performed in triplicate. *P<0.05, **P<0.01.
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To investigate the mechanism of A. muciniphila ameliorating the hyperlipidemia in
CREBH KO mice, we tested the mRNA expression levels of LPL co-factors, apoC2,
apoA4, apoA5, by real-time PCR in vehicle and A. muciniphila treated WT and CREBH
KO mice. It has been reported that the depletion of CREBH in mice would depress the
expression of LPL co-factors, inducing inefficient hydrolysis of lipoprotein TGs by LPL
and thus leading to hypertriglyceridemia. However, there were no significant differences
in the mRNA expression of apoA4, apoA5 or apoC2 between vehicle and A. muciniphila
groups (Figure 4 A B C). We had investigated that the expression of LDL receptor in the
liver of CREBH KO mice treated with A. muciniphila was significantly higher than that
of control group. To further confirm whether LDL receptor signaling could be
upregulated by A. muciniphila colonization to help clearing VLDL remnants, we used gel
filtration fast-phase liquid chromatography (FPLC) to analyze the plasma lipoprotein
content. The TG level in the VLDL, IDL and LDL particles in A. muciniphila group was
significantly decreased, suggesting that the clearance of IDL and LDL was increased by
A. muciniphila colonization (Figure 3 A). The CHOL level in VLDL, IDL, LDL and
large HDL was also slightly decreased in A. muciniphila group (Figure 3 B). This shows
that A. muciniphila treatment may upregulate the clearance of VLDL remnants by LDL
receptor pathway. To confirm the specificity of LDL receptor in the effect of A.
muciniphila on the host, we administrated A. muciniphila and vehicle to two groups of
LDL receptor KO mice every other day for two weeks respectively. A. muciniphila
administration didn’t ameliorate the hypercholesterolemia induced by LDL receptor
depletion (Figure 5 B). Oral glucose tolerance test also revealed that A. muciniphila failed
to improve insulin sensitivity of LDL receptor KO mice (Figure 5 A), indicating that
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LDL receptor was crucial in the regulatory role of A. muciniphila.

(Shen et al. ATVB 2016)
Figure 3. CREBH KO mice were treated with 200 µL of vehicle or A. muciniphila by
gavage for 2 weeks. Gel filtration fast-phase liquid chromatography (FPLC) was used to
analyze the plasma lipoprotein content in mice. A) The TG level in the VLDL, IDL and
LDL particles in A. muciniphila group was significantly decreased. B) The CHOL level
in VLDL, IDL, LDL and large HDL was slightly decreased in A. muciniphila group.
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(Shen et al. ATVB 2016)
Figure 4. Impact of A. muciniphila on the expression of LPL co-factors. WT and
CREBH KO mice were separately subjected with 200 µL vehicle or A. muciniphila every
two days for 2 weeks. The mRNA expression levels of apoA4, apoA5 or apoC2 were
analyzed. Results are shown as means ± SD for two experiments that were performed in
triplicate. *P<0.05, **P<0.01.
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(Shen et al. ATVB 2016)
Figure 5. Effect of A. muciniphila on LDL receptor KO mice. A. muciniphila and vehicle
were administrated to two groups of LDL receptor KO mice every other day for two
weeks respectively. A) Oral glucose tolerance test was conducted after A. muciniphila
administration. The result revealed that A. muciniphila failed to improve insulin
sensitivity of LDL receptor KO mice. B) Plasma lipid concentration analysis showed that
A. muciniphila administration didn’t ameliorate the hypercholesterolemia induced by
LDL receptor depletion. Results are shown as means ± SD for two experiments that were
performed in triplicate. *P<0.05, **P<0.01.
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To determine whether A. muciniphila inoculation impacts the CM assembly and secretion
in the intestinal enterocytes, we treated CREBH KO mice with vehicle or A. muciniphila
for two weeks followed by an in vivo CM collection assay which is described in
Materials and Methods. Lipid was extracted from the jejunum of both groups which was
collected 2 hours after olive oil gavage. Measurement of lipid contents showed that the
TG and CHOL contents in the jejunum of both groups were the same (Figure 6 A). This
meant that A. muciniphila colonization didn’t impair the fat absorption or CM
biosynthesis in the intestine. To test the clearance rate of CMs in the circulation, a
vitamin A excursion assay was conducted as described in Materials and Methods. The
[3H]-retinol which was mixed with olive oil treated by gavage was used to synthesize
fatty acid esters in the enterocytes. This kind of [3H]-labeled fatty acid esters was
incorporated into CMs, secreted into the blood and removed by the liver [100]. At 3.5,
7.5 and 11 hours after oil gavage, the [3H] level in the plasma of A. muciniphila treated
CREBH KO mice was significantly lower than that of vehicle treated mice (Figure 6 B),
suggesting a faster clearance of CMs by the liver in A. muciniphila treated mice. This
increased clearance may be mediated by the increased expression of LDL receptors in the
liver of A. muciniphila group.
To determine whether inactive A. muciniphila could also regulate the CM metabolism of
the host, we subjected two groups of CREBH KO mice to CM collection assay which had
already been administrated with alive A. muciniphila or heat-inactive A. muciniphila for
two weeks. The protein level of apoB in the plasma of heat-inactive A. muciniphila group
was significantly higher than that of A. muciniphila group before and at 2 hours after
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olive oil and poloxamer treatment (Figure 7 A B), indicating that heat-inactive A.
muciniphila was not able to play a regulatory role in CM clearance.
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(Shen et al. ATVB 2016)
Figure 6. Impact of A. muciniphila inoculation on the CM metabolism. CREBH KO mice
was administrated with vehicle or A. muciniphila every two days for two weeks followed
by an in vivo CM collection assay. A) Lipid was extracted from the jejunum of both
groups of mice which was collected 2 hours after olive oil gavage. The TG and CHOL
contents in the jejunum of both groups were the same. B) A vitamin A excursion assay
was conducted to test the clearance rate of CMs in the circulation. The [3H]-retinol was
mixed with olive oil and subjected to the mice by gavage. At 3.5, 7.5 and 11 hours after
oil gavage, the [3H] levels in the plasma of both groups of mice were analyzed. Results
are shown as means ± SD for two experiments that were performed in triplicate. *P<0.05,
**P<0.01.
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(Shen et al. ATVB 2016)
Figure 7. Two groups of CREBH KO mice were subjected to CM collection assay which
had already been administrated with alive A. muciniphila or heat-inactive A. muciniphila
for two weeks. The protein levels of apoB48 and apoB100 in the plasma of heat-inactive
A. muciniphila group and A. muciniphila group before (A) and at 2 hours after (B) olive
oil and poloxamer treatment were compared. Results are shown as means ± SD for two
experiments that were performed in triplicate. *P<0.05, **P<0.01.
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Since hyperlipidemia is closely related with hepatic inflammation and ER stress, we
hypothesize that increased colonization of A. muciniphila could alleviate the ER stress
and inflammation induced by CREBH depletion. Both WT and CREBH KO mice were
subjected with vehicle or A. muciniphila administration by oral gavage every two days
for two weeks. Protein levels of biomarkers of ER stress and inflammation in the
hepatocytes of the mice were measured by immuoblotting analysis. It was found that the
expression of TLR-4, an important proinflammatory factor associated with circulating
lipopolysaccharide (LPS) level, was not affected by A. muciniphila inoculation (Figure 8).
The phosphorylation of JNK1 and JNK2, the inflammation transcription factors which
was stimulated by CREBH depletion, was significantly decreased by A. muciniphila
administration in CREBH KO mice (Figure 8). In WT mice, the colonization of A.
muciniphila also inhibited the phosphorylation of JNK1 and JNK2 (Figure 8). The
expression level of ER stress biomarker, GRP94, was also increased by the depletion of
CREBH, and was reduced by A. muciniphila inoculation (Figure 8). However, in the liver
of WT mice, the GRP94 level was not significantly affected by A. muciniphila treatment
(Figure 8). These results demonstrate that increased colonization of A. muciniphila in
CREBH KO mice may ameliorate the inflammation and ER stress in the hepatocytes
which were induced by CREBH depletion.
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(Shen et al. ATVB 2016)
Figure 8. Impact of increased colonization of A. muciniphila on ER stress and
inflammation induced by CREBH depletion. Both WT and CREBH KO mice were
subjected with vehicle or A. muciniphila administration by oral gavage every two days
for two weeks. Protein levels of biomarkers of ER stress and inflammation in the
hepatocytes of the mice were measured by immuoblotting analysis. The expression of ER
stress biomarker, GRP94, and inflammation transcription factors, JNK1 and JNK2
phosphorylation, were stimulated by the depletion of CREBH, and reduced by A.
muciniphila inoculation. Results are shown as means ± SD for two experiments that were
performed in triplicate. *P<0.05, **P<0.01.
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Part 2
Determine the beneficial property of Fenugreek on genetic induced hyperlipidemia
To investigate the effect of fenugreek seeds on genetic induced hyperlipidemia, two
groups of CREBH KO mice were respectively fed with control chow diet and chow diet
mixed with 2% of fenugreek seeds for 7 weeks. CREBH depletion in mice induced a
significantly higher TG level in the plasma compared with that of WT mice. At the end of
the 7-week feeding, the mice were fasted for 12 hours and the plasma lipid contents of
the mice were measured. The TG level of the fenugreek fed CREBH KO mice was
significantly lower than that of control group, suggesting that fenugreek helped to
alleviate the hypertriglyceridemia in CREBH KO mice (Figure 9 A). The CHOL level in
the plasma of the mice was not affected by fenugreek treatment (Figure 9 B).
Hyperlipidemia was closely related with insulin resistance. To verify whether fenugreek
seeds were able to regulate the glucose sensitivity, we fed two groups of C57BL/6J (WT)
mice with high fat diet to induce insulin resistance, and added 2% fenugreek seeds into
the diet of one group. The mice were fed the special diets for 7 weeks and then subjected
to glucose tolerance test and insulin tolerance test. After 12-hour fasting, a dose of
glucose or insulin was injected into enterocoelia of the mice and glucose concentration in
the blood was measured. The blood glucose level of the mice fed with fenugreek
decreased faster than that of high fat diet fed mice in both glucose and insulin tolerance
tests (Figure 10 A B). This indicates that the uptake of the glucose by adipose tissue and
liver was enhanced and insulin resistance was ameliorated by fenugreek seed feeding.
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Figure 9. Fenugreek seeds were able to alleviate the hypertriglyceridemia induced by
CREBH depletion. Two groups of CREBH KO mice were respectively fed with control
chow diet and chow diet mixed with 2% of fenugreek seeds for 7 weeks. After the 7week feeding, the mice were fasted for 12 hours and the plasma lipid contents, TG (A)
and CHOL (B), of the mice were measured. Results are shown as means ± SD for two
experiments that were performed in triplicate. *P<0.05, **P<0.01.
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To demonstrate whether the low TG level in the plasma of fenugreek seed feeding
CREBH KO mice was induced by decreased assembly and secretion of VLDL in the liver,
we analyzed the expression level of apoB100 in the liver of two groups of CREBH KO
mice which were fed chow diet or chow diet mixed with 2% fenugreek seeds for 7 weeks
by immunoblotting analysis. The result showed that the protein level of apoB100 in the
liver of fenugreek group was significantly lower compared with that of chow diet group
(Figure 11 A), indicating that fenugreek seeds treatment inhibited the biosynthesis of
apoB100. Lipid was then extracted from the liver and TG and CHOL contents were
measured. TG content in the liver of chow diet group was much higher than that of
fenugreek group, while CHOL content was comparable in the liver of both groups
(Figure 11 B). The results suggests than fenugreek seeds suppressed the apoB100
biosynthesis and inhibited the assembly of VLDL in the liver of CREBH KO mice. This
may further lead to the decreased secretion of VLDL into the circulation and helped to
attenuate the hypertriglyceridemia induced by depletion of CREBH.
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Figure 10. Effect of fenugreek seeds on insulin sensitivity of mice. Two groups of
C57BL/6J (WT) mice were fed with high fat diet to induce insulin resistance, and 2%
fenugreek seeds were added into the diet of one group. The mice were fed the special
diets for 7 weeks and then subjected to glucose tolerance test and insulin tolerance test.
After 12-hour fasting, a dose of glucose or insulin was injected into enterocoelia of the
mice and glucose concentration in the blood was measured. The results of glucose
tolerance test (A) and insulin tolerance test (B) were shown. Results are shown as means
± SD for two experiments that were performed in triplicate. *P<0.05, **P<0.01.
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Figure 11. Impact of fenugreek seeds on VLDL assembly. Two groups of CREBH KO
mice were fed with chow diet or chow diet mixed with 2% fenugreek seeds for 7 weeks.
A) The protein level of apoB100 in the liver of two groups of mice were measured by
immunoblotting analysis. Fenugreek seeds treatment significantly reduced the expression
of apoB100 in the liver of the mice. B) Lipid was extracted from the liver and TG and
CHOL contents were measured. TG content in the liver of chow diet group was much
higher than that of fenugreek group, while CHOL content was comparable in the liver of
both groups. Results are shown as means ± SD for two experiments that were performed
in triplicate. *P<0.05, **P<0.01.

44

Chapter Four
Discussion
Part 1
A. muciniphila ameliorates hyperlipidemia by enhancing the expression of hepatic
LDL receptors to facilitate the clearance of TG rich lipoproteins and alleviating
hepatic ER stress and metabolic inflammation
Pervious study in our lab has revealed that colonization of A. muciniphila didn't affect the
lipid content in the plasma of WT mice, whose plasma lipid concentration was within
normal levels. However, the inoculation of A. muciniphila in CREBH KO mice, which
suffered from hypertriglyceridemia because of CREBH depletion, significantly reduced
the plasma TG level of the mice after 2-week treatment. We further explored the impact
of A. muciniphila on lipid metabolism of the host, and found that after acute lipid
treatment, the protein concentrations of apoB48 and apoB100 in A. muciniphila-WT mice
were significantly lower than that of vehicle-WT mice, indicating lower CMs and VLDL
content in the plasma of A. muciniphila group. This shows that A. muciniphila was able to
protect the mice from instantaneous fat load. FPLC analysis showed that the TG content
of VLDL, IDL and LDL particles in the plasma of CREBH KO mice was decreased by
the inoculation of A. muciniphila. At the same time, heat-inactive A. muciniphila failed to
ameliorate the extremely high level of TG in the plasma of CREBH KO mice or improve
its insulin sensitivity, suggesting that A. muciniphila had to be active to play regulatory
role in the metabolism of the host. These data imply that the effect of A. muciniphila on
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the host may only be exerted when the host is within abnormal conditions, like
hyperlipidemia or metabolic complications.
Previous study in our lab also investigated that the hepatic expression of LDL receptors
in CREBH KO mice was remarkably increased by A. muciniphila administration. LDL
receptor is important in mediating the clearance of VLDL remnants, IDL particles into
the liver from circulation. Endogenously synthesized lipids are secreted from the liver via
VLDL particles and are partially cleared via LDL receptor pathway. TGs in VLDLs are
hydrolyzed by LPL in the blood to form IDLs. A part of the IDLs are rapidly
endocytosed into hepatocytes mediated by the interaction of LDL receptor in the
membrane of hepatocytes and apoE, a major ligand in IDLs. The other portion of IDL
particles are converted to LDL by hepatic lipase. Administration of A. muciniphila to
LDL receptor KO mice proved that A. muciniphila was not able to alter the abnormal
lipid content in the plasma of the mice. In addition, the glucose sensitivity of LDL
receptor KO mice was not improved by A. muciniphila treatment. These results suggested
that A. muciniphila inoculation alleviated the hyperlipidemia by stimulating the
expression of LDL receptors and promoting the uptake of lipoprotein particles. FPLC
analysis also confirmed that the CHOL contents of VLDL, IDL, LDL and larger HDL
particles in the plasma of CREBH KO mice are slightly reduced by increased
colonization of A. muciniphila, consisting with the enhanced expression of hepatic LDL
receptors. One of the important factors that causes hypertriglyceridemia in CREBH KO
mice is impaired expression of apoA4, apoA5 and apoC2, which are the coactivators of
LPL [56]. This impairment suppressed the LPL activity and inhibited the hydrolysis of
TGs in lipoproteins [26]. Our study revealed that A. muciniphila treatment didn’t alter the
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mRNA level of apoA4, apoA5 or apoC2, the expression of which are defected by
CREBH depletion. This indicates that the regulatory role of A. muciniphila is not
mediated by restoring the ineffective LPL activity.
Hyperlipidemia is closely related with hepatic stress, insulin resistance and inflammation
responds [103-105]. By analyzing the expression of the biomarkers of hepatic ER stress
and metabolic inflammation signaling in A. muciniphila treated CREBH KO mice, we
determined that A. muciniphila colonization helped to attenuate ER stress and
inflammation stimulated by CREBH depletion. Moreover, the insulin sensitivity of the
mice was improved by A. muciniphila treatment.
In summary, the inoculation of A. muciniphila improves the hyperlipidemia, induced by
genetic depletion, for instance, of the host mice. The underlying mechanisms of the
process would be enhancing the expression of hepatic LDL receptors to facilitate the
clearance of TG rich lipoproteins and alleviating hepatic ER stress and metabolic
inflammation, which could further ameliorate the host’s insulin sensitivity. Further
studies should be conducted to explore the exact regulatory impact of A. muciniphila and
the detailed mechanism of the process.

Part 2
Fenugreek seed alleviates hyperlipidemia by inhibiting the assembly of VLDL
particles and attenuating insulin resistance
In this study, we investigated the impact of fenugreek seeds on the hyperlipidemia of
CREBH KO mice. 7-week treatment of fenugreek rich diet (2%) apparently reduced the
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TG level in the plasma of the mice, suggesting the anti-hyperlipidemia property of
fenugreek seeds. Fenugreek feeding on another mice model, WT mice fed with high fat
diet, revealed that fenugreek ameliorated the impaired insulin sensitivity and enhanced
the uptake of glucose into liver and adipose tissue. This further may exert beneficial
effect on improving hyperlipidemia of mice. More studies should be conducted to explore
the underlying mechanism that fenugreek seeds improve insulin sensitivity.
A major part of the TGs that caused hypertriglyceridemia in CREBH KO mice is in the
VLDL particles in the blood of the mice [106]. Our study demonstrated that fenugreek
seeds rich diet inhibited the expression of apoB100 in the liver of CREBH KO mice, and
reduced the hepatic TG level. This indicated that fenugreek seeds are able to suppress the
biosynthesis of apoB100 and the assembly and secretion of VLDL in the liver of CREBH
KO mice, which induced the decrease of the TG contents in the circulation. Further
researches are needed to find out whether fenugreek seeds could accelerate the clearance
of lipoproteins in the blood of the mice.
In summary, fenugreek seeds have a beneficial property to alleviate hyperlipidemia
induced by CREBH depletion in mice. Fenugreek seeds rich diet also help to attenuate
insulin resistance. A potential mechanism of the anti-hyperlipidemia property of
fenugreek seeds is that they could inhibit the biosynthesis of apoB100 and suppress the
assembly of VLDL particles. Further studies are needed to investigate the mechanism of
how fenugreek seeds impact lipoprotein metabolism and the effect of fenugreek seeds on
hepatic stress and inflammatory responds of the mice.
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